These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23414404)

  • 21. Mucosal AIDS vaccines.
    Bourinbaiar AS; Metadilogkul O; Jirathitikal V
    Viral Immunol; 2003; 16(4):427-45. PubMed ID: 14733732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "HIV-peplotion vaccine"--a novel approach to protection against AIDS by transepithelial transport of viral peptides to Langerhans cells for long-term antiviral CTL response. (A review).
    Becker Y
    Acta Microbiol Immunol Hung; 1996; 43(1):1-17. PubMed ID: 8806938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
    Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
    J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidating the elite: mechanisms of control in HIV-1 infection.
    O'Connell KA; Bailey JR; Blankson JN
    Trends Pharmacol Sci; 2009 Dec; 30(12):631-7. PubMed ID: 19837464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virus-like particles as HIV-1 vaccines.
    Doan LX; Li M; Chen C; Yao Q
    Rev Med Virol; 2005; 15(2):75-88. PubMed ID: 15484204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
    Mooij P; Balla-Jhagjhoorsingh SS; Koopman G; Beenhakker N; van Haaften P; Baak I; Nieuwenhuis IG; Kondova I; Wagner R; Wolf H; Gómez CE; Nájera JL; Jiménez V; Esteban M; Heeney JL
    J Virol; 2008 Mar; 82(6):2975-88. PubMed ID: 18184713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-like particles: designing an effective AIDS vaccine.
    Young KR; McBurney SP; Karkhanis LU; Ross TM
    Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Top stories of 2008. Crash and burn of HIV vaccine candidates.
    del Rio C
    AIDS Clin Care; 2009 Jan; 21(1):4. PubMed ID: 19219958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells.
    Van den Bosch GA; Van Gulck E; Ponsaerts P; Nijs G; Lenjou M; Apers L; Kint I; Heyndrickx L; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    J Immunother; 2006; 29(5):512-23. PubMed ID: 16971807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
    Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
    Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 34. Enveloped virus-like particle platforms: vaccines of the future?
    Pitoiset F; Vazquez T; Bellier B
    Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
    Salmon-Céron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelièvre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Lévy Y; Launay O;
    AIDS; 2010 Sep; 24(14):2211-23. PubMed ID: 20625264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
    Newman MJ
    Curr Opin Investig Drugs; 2002 Mar; 3(3):374-8. PubMed ID: 12054082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines.
    Chen CW; Saubi N; Joseph-Munné J
    Front Immunol; 2020; 11():573157. PubMed ID: 33117367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier.
    Kawano M; Matsui M; Handa H
    Expert Rev Vaccines; 2013 Feb; 12(2):199-210. PubMed ID: 23414410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.
    Gao Y; Wijewardhana C; Mann JFS
    Front Immunol; 2018; 9():345. PubMed ID: 29541072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.